Twin Health, a company that uses artificial intelligence to create personalized models of individual metabolisms, has secured $50 million in funding from Singapore’s Temasek and other investors.

The company aims to reverse, improve, and prevent chronic metabolic diseases, such as type 2 diabetes, obesity, and fatty liver, that affect millions of people worldwide.

Twin Health’s technology, called “Whole Body Digital Twin”, collects data from wearable sensors, clinical labs, and self-reports, and provides guidance on nutrition, sleep, activity, and stress through a mobile app and a clinical care team.

The company claims to have completed the world’s first randomized controlled trial for reversing chronic metabolic disease using digital twin technology, showing significant reductions in blood sugar levels, weight, and medication use among participants.

Jahangir Mohammed, CEO of Twin Health, said the funding will help scale the availability and deployment of the technology to more health plans and employer partners, achieving lower costs, better outcomes, and higher satisfaction.

Kevin Johnson, former CEO of Starbucks and a board member of Twin Health, praised the company’s innovative approach and its potential to change the lives of people suffering from chronic metabolic diseases.

SGX and Temasek form JV to advance digital asset infrastructure in capital markets

SuperSeed Fund leads $3.4mn investment round into Garvis AI Ltd